Tositumomab
From Proteopedia
(Difference between revisions)
| Line 23: | Line 23: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ||
| - | ! Tositumomab | ||
| - | ! Ofatumumab | ||
| - | ! Rituximab | ||
| - | ! Ibritumomab | ||
| - | |- | ||
| - | ! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ||
! Tositumomab | ! Tositumomab | ||
! Ofatumumab | ! Ofatumumab | ||
Revision as of 16:54, 12 December 2010
Pharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | 167000 | 205800 | Ibritumomab |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | 64.8 | 68 | 206 | Ibritumomab |
| AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | Ibritumomab |
| Clearance (L/h) | .078 | .017 | .009 | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage | Tositumomab | 500 mg (4th Infusion) | 325 mg/m2 (4th Infusion) | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
